Epithelial cell responses to infection with human papillomavirus

Clinical Microbiology Reviews

Volumn 25, Issue 2, 2012, Pages 215-222

  Stanley, Margaret A ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CAPSID PROTEIN; CAPSID PROTEIN L1; DNA POLYMERASE; HEPARIN; INFLAMMASOME; INTERFERON; INTERFERON REGULATORY FACTOR 1; INTERFERON STIMULATED GENE FACTOR 3; INTERLEUKIN 1; INTERLEUKIN 1BETA CONVERTING ENZYME; MUCOSAL ADDRESSIN CELL ADHESION MOLECULE 1; NEUTRALIZING ANTIBODY; PATTERN RECOGNITION RECEPTOR; PROTEIN KINASE TYK2; PROTEIN P53; STAT1 PROTEIN; STAT2 PROTEIN; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; VIRUS ANTIGEN; VIRUS DNA; VIRUS LIKE PARTICLE VACCINE; VIRUS PROTEIN; WART VIRUS VACCINE;

ADAPTIVE IMMUNITY; ANTIBODY BLOOD LEVEL; ANTIGEN PRESENTING CELL; CANCER GROWTH; CANCER RISK; CD8+ T LYMPHOCYTE; CELL CYCLE; CELL DIFFERENTIATION; CELL INFILTRATION; CLINICAL TRIAL (TOPIC); CONDYLOMA ACUMINATUM; CONTROLLED CLINICAL TRIAL (TOPIC); CYTOKINE RESPONSE; DENDRITIC CELL; DNA REPLICATION; DOWN REGULATION; EFFECTOR CELL; ENZYME ACTIVATION; EPISOME; EPITHELIUM CELL; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENE TRANSLOCATION; HOST RESISTANCE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMORAL IMMUNITY; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INNATE IMMUNITY; KERATINOCYTE; MONONUCLEAR CELL; NONHUMAN; PAPILLOMAVIRUS INFECTION; PASSIVE IMMUNIZATION; PHENOTYPE; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS EPITHELIUM; STEM CELL; TH1 CELL; TRANSCRIPTION INITIATION; UBIQUITINATION; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VERRUCA VULGARIS; VIROGENESIS; VIRUS ASSEMBLY; VIRUS ATTACHMENT; VIRUS DNA CELL DNA INTERACTION; VIRUS ENTRY; VIRUS GENE; VIRUS GENOME; VIRUS LIKE AGENT; VIRUS ONCOGENE; VIRUS REPLICATION; WART VIRUS;

EPITHELIAL CELLS; HOST-PATHOGEN INTERACTIONS; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES;

ANIMALIA; HUMAN PAPILLOMAVIRUS;

EID: 84859550524     PISSN: 08938512     EISSN: 10986618     Source Type: Journal    
DOI: 10.1128/CMR.05028-11     Document Type: Review

References (84)

1. Akira S, Hemmi H. 2003. Recognition of pathogen-associated molecular patterns by TLR family. Immunol. Lett. 85:85-95.
2. Alazawi W, et al. 2002. Changes in cervical keratinocyte gene expression associated with integration of human papillomavirus 16. Cancer Res. 62: 6959-6965.
3. Arany I, Goel A, Tyring SK. 1995. Interferon response depends on viral transcription in human papillomavirus-containing lesions. Anticancer Res. 15:2865-2869.
4. Arend WP, Palmer G, Gabay C. 2008. IL-1, IL-18, and IL-33 families of cytokines. Immunol. Rev. 223:20-38.
5. Bedoui S, et al. 2009. Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells. Nat. Immunol. 10:488-495.
6. Bernard HU, et al. 2010. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 401: 70-79.
7. Black AP, et al. 2007. Human keratinocyte induction of rapid effector function in antigen-specific memory CD4+ and CD8+ T cells. Eur. J. Immunol. 37:1485-1493.
8. Bosch FX, et al. 2008. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 26(Suppl 10):K1-K16.
9. Breitburd F, et al. 1995. Immunization with virus-like particles from cotton tail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J. Virol. 69:3959-3963.
10. Carter JJ, et al. 2000. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J. Infect. Dis. 181:1911-1919.
11. Carter JJ, et al. 1996. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J. Infect. Dis. 174:927-936.
12. Chow LT, Broker TR, Steinberg BM. 2010. The natural history of human papillomavirus infections of the mucosal epithelia. APMIS 118:422-449.
13. Coleman N, et al. 1994. Immunological events in regressing genital warts. Am. J. Clin. Pathol. 102:768-774.
14. Coleman N, et al. 1993. Characterization and functional analysis of the expression of intercellular adhesion molecule-1 in human papillomavirusrelated disease of cervical keratinocytes. Am. J. Pathol. 143:355-367.
15. Coleman N, Stanley MA. 1994. Characterization and functional analysis of the expression of vascular adhesion molecules in human papillomavirus related disease of the cervix. Cancer 74:884-892.
16. Da Silva DM, Fausch SC, Verbeek JS, Kast WM. 2007. Uptake of human papillomavirus virus-like particles by dendritic cells is mediated by Fcgamma receptors and contributes to acquisition of T cell immunity. J. Immunol. 178:7587-7597.
17. Day PM, Gambhira R, Roden RB, Lowy DR, Schiller JT. 2008. Mechanisms of human papillomavirus type 16 neutralization by l2 crossneutralizing and l1 type-specific antibodies. J. Virol. 82:4638-4646.
18. Day PM, et al. 2010. In vivo mechanisms of vaccine-induced protection against HPV infection. Cell Host Microbe 8:260-270.
19. Day PM, Schiller JT. 2009. The role of furin in papillomavirus infection. Future Microbiol. 4:1255-1262.
20. Day PM, et al. 2007. Neutralization of human papillomavirus with monoclonal antibodies reveals different mechanisms of inhibition. J. Virol. 81:8784-8792.
21. de Jong A, et al. 2002. Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res. 62:472-479.
22. Dillner J, et al. 2010. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 341:c3493.
23. Doorbar J. 2005. The papillomavirus life cycle. J. Clin. Virol. 32:S7-S15.
24. Doorbar J. 2007. Papillomavirus life cycle organization and biomarker selection. Dis. Markers 23:297-313.
25. Dowen SE, et al. 2003. Amplification of chromosome 5p correlates with increased expression of Skp2 in HPV-immortalized keratinocytes. Oncogene 22:2531-2540.
26. Fausch SC, Da Silva DM, Rudolf MP, Kast WM. 2002. Human papillomavirus virus-like particles do not activate Langerhans cells: a possible immune escape mechanism used by human papillomaviruses. J. Immunol. 169:3242-3249.
27. Garland SM, et al. 2007. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N. Engl. J. Med. 356:1928-1943.
28. Ghim S, et al. 2000. Spontaneously regressing oral papillomas induce systemic antibodies that neutralize canine oral papillomavirus. Exp. Mol. Pathol. 68:147-151.
29. Giuliano AR, et al. 2011. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N. Engl. J. Med. 364:401-411.
30. Gray E, et al. 2010. In vitro progression of human papillomavirus 16 episome-associated cervical neoplasia displays fundamental similarities to integrant-associated carcinogenesis. Cancer Res. 70:4081-4091.
31. Harro CD, et al. 2001. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J. Natl. Cancer Inst. 93:284-292.
32. Herdman MT, et al. 2006. Interferon-beta treatment of cervical keratinocytes naturally infected with human papillomavirus 16 episomes promotes rapid reduction in episome numbers and emergence of latent integrants. Carcinogenesis 27:2341-2353.
33. International Agency for Research on Cancer. 1996. Human papillomaviruses, vol 64. Meeting of IARC Working Group on 6 to 13 June 1995. International Agency for Research on Cancer, Lyon, France.
34. Jablonska S, Dabrowski J, Jakubowicz K. 1972. Epidermodysplasia verruciformis as a model in studies on the role of papovaviruses in oncogenesis. Cancer Res. 32:583-589.
35. Jain S, Moore RA, Anderson DM, Gough GW, Stanley MA. 2006. Cell-mediated immune responses to COPV early proteins. Virology 356: 23-34.
36. Kalali BN, et al. 2008. Double-stranded RNA induces an antiviral defense status in epidermal keratinocytes through TLR3-, PKR-, and MDA5/RIGI- mediated differential signaling. J. Immunol. 181:2694-2704.
37. Kanodia S, Fahey LM, Kast WM. 2007. Mechanisms used by human papillomaviruses to escape the host immune response. Curr. Cancer Drug Targets 7:79-89.
38. Karim R, et al. 2011. Human papillomavirus deregulates the response of a cellular network comprising of chemotactic and proinflammatory genes. PLoS One 6:e17848.
39. Kines RC, Thompson CD, Lowy DR, Schiller JT, Day PM. 2009. The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding. Proc. Natl. Acad. Sci. U. S. A. 106:20458-20463.
40. Kobayashi A, et al. 2004. Functional attributes of mucosal immunity in cervical intraepithelial neoplasia and effects of HIV infection. Cancer Res. 64:6766-6774.
41. Kobayashi A, Weinberg V, Darragh T, Smith-McCune K. 2008. Evolving immunosuppressive microenvironment during human cervical carcinogenesis. Mucosal Immunol. 1:412-420.
42. Lacey CJ, Lowndes CM, Shah KV. 2006. Chapter 4: burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 24(Suppl 3):S35-S41.
43. Le Bon A, Tough DF. 2002. Links between innate and adaptive immunity via type I interferon. Curr. Opin. Immunol. 14:432-436.
44. Martinon F, Mayor A, Tschopp J. 2009. The inflammasomes: guardians of the body. Annu. Rev. Immunol. 27:229-265.
45. McKenzie J, et al. 1991. Immunocytochemical characterization of large granular lymphocytes in normal cervix and HPV associated disease. J. Pathol. 165:75-80.
46. Medzhitov R, Janeway CAJ. 1997. Innate immunity: the virtues of a non-clonal system of recognition. Cell 91:295-298.
47. Merad M, Ginhoux F, Collin M. 2008. Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells. Nat. Rev. Immunol. 8:935-947.
48. Miller LS, Modlin RL. 2007. Human keratinocyte Toll-like receptors promote distinct immune responses. J. Invest. Dermatol. 127:262-263.
49. Moody CA, Laimins LA. 2010. Human papillomavirus oncoproteins: pathways to transformation. Nat. Rev. Cancer 10:550-560.
50. Moscicki AB, Schiffman M, Kjaer S, Villa LL. 2006. Chapter 5: updating the natural history of HPV and anogenital cancer. Vaccine 24(Suppl 3): S42-S51.
51. Myers SR, Leigh IM, Navsaria H. 2007. Epidermal repair results from activation of follicular and epidermal progenitor keratinocytes mediated by a growth factor cascade. Wound Repair Regen. 15:693-701.
52. Nasu K, Narahara H. 2010. Pattern recognition via the Toll-like receptor system in the human female genital tract. Mediators Inflamm. 2010: 976024.
53. Nestle FO, Di Meglio P, Qin JZ, Nickoloff BJ. 2009. Skin immune sentinels in health and disease. Nat. Rev. Immunol. 9:679-691.
54. Nicholls PK, et al. 1999. Naturally occurring, nonregressing canine oral papillomavirus infection: host immunity, virus characterization, and experimental infection. Virology 265:365-374.
55. Nicholls PK, et al. 2001. Regression of canine oral papillomas is associated with infiltration of CD4+and CD8+lymphocytes. Virology 283:31-39.
56. Orth G, Jablonska S, Breitburd F, Favre M, Croissant O. 1978. The human papillomaviruses. Bull. Cancer 65:151-164.
57. Paavonen J, et al. 2009. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374:301-314.
58. Park JS, et al. 2000. Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7- mediated immune evasion mechanism in cervical carcinogenesis. J. Biol. Chem. 275:6764-6769.
59. Parkin DM, Bray F. 2006. Chapter 2: the burden of HPV-related cancers. Vaccine 24(Suppl 3):S11-S25.
60. Pett M, Coleman N. 2007. Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis? J. Pathol. 212:356-367.
61. Pett MR, et al. 2004. Acquisition of high-level chromosomal instability is associated with integration of human papillomavirus type 16 in cervical keratinocytes. Cancer Res. 64:1359-1368.
62. Pett MR, et al. 2006. Selection of cervical keratinocytes containing integrated HPV16 associates with episome loss and an endogenous antiviral response. Proc. Natl. Acad. Sci. U. S. A. 103:3822-3827.
63. Reusch MK, Mansbridge JN, Nickoloff BJ, Morhenn VB. 1991. Immunophenotyping of skin cells during healing of suction blister injury. Dermatologica 183:179-183.
64. Roberts JN, et al. 2007. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat. Med. 13: 857-861.
65. Ronco LV, Karpova AY, Vidal M, Howley PM. 1998. Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev. 12:2061-2072.
66. Safaeian M, et al. 2010. Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. J. Natl. Cancer Inst. 102:1653-1662.
67. Sapp M, Bienkowska-Haba M. 2009. Viral entry mechanisms: human papillomavirus and a long journey from extracellular matrix to the nucleus. FEBS J. 276:7206-7216.
68. Shope RE. 1937. Immunization of rabbits to infectious papillomatosis. J. Exp. Med. 65:607-624.
69. Stanley M. 2006. Immune responses to human papillomavirus. Vaccine 24(Suppl 1):S16-S22.
70. Stanley MA. 2002. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin. Exp. Dermatol. 27:571-577.
71. Stanley MA, et al. 2001. Intra-epithelial vaccination with COPV L1 DNA by particle-mediated DNA delivery protects against mucosal challenge with infectious COPV in beagle dogs. Vaccine 19:2783-2792.
72. Stanley MA, Pett M. 2007. Papillomaviruses, p 448-472. In Mahy BWJ, ter Meulen V (ed), Topley & Wilson's microbiology & microbial infections. Virology, vol 2, 10th ed. Wiley-Blackwell, Hoboken, NJ.
73. Suzich JA, et al. 1995. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc. Natl. Acad. Sci. U. S. A. 92:11553-11557.
74. Trimble CL, et al. 2010. Human papillomavirus 16-associated cervical intraepithelial neoplasia in humans excludes CD8 T cells from dysplastic epithelium. J. Immunol. 185:7107-7114.
75. Um SJ, et al. 2002. Abrogation of IRF-1 response by high-risk HPV E7 protein in vivo. Cancer Lett. 179:205-212.
76. Vinokurova S, et al. 2008. Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res. 68:307-313.
77. Welters MJ, et al. 2003. Frequent display of human papillomavirus type 16 E6-specific memory T-helper cells in the healthy population as witness of previous viral encounter. Cancer Res. 63:636-641.
78. Wentzensen N, Vinokurova S, von Knebel Doeberitz M. 2004. Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female lower genital tract. Cancer Res. 64:3878-3884.
79. Woo Y, et al. 2008. Characterising the local immune responses in cervical intraepithelial neoplasia: a cross-sectional and longitudinal analysis. BJOG 115:1616-1622.
80. Woo YL, et al. 2010. A prospective study on the natural course of lowgrade squamous intraepithelial lesions and the presence of HPV16 E2-, E6- and E7-specific T-cell responses. Int. J. Cancer 126:133-141.
81. Yan M, et al. 2005. Activation of dendritic cells by human papillomavirus-like particles through TLR4 and NF-kappaB-mediated signalling, moderated by TGF-beta. Immunol. Cell Biol. 83:83-91.
82. Yang R, et al. 2004. Human papillomavirus type-16 virus-like particles activate complementary defense responses in key dendritic cell subpopulations. J. Immunol. 173:2624-2631.
83. Zhao KN, Gu W, Fang NX, Saunders NA, Frazer IH. 2005. Gene codon composition determines differentiation-dependent expression of a viral capsid gene in keratinocytes in vitro and in vivo. Mol. Cell. Biol. 25:8643-8655.
84. Zur Hausen H, de Villiers EM, Gissmann L. 1981. Papillomavirus infections and human genital cancer. Gynecol. Oncol. 12:S124-S128.